Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $23.4 million.

  • Northwest Biotherapeutics' Non-Current Assets fell 297.57% to $23.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.4 million, marking a year-over-year decrease of 297.57%. This contributed to the annual value of $22.7 million for FY2024, which is 452.4% down from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Non-Current Assets of $23.4 million as of Q3 2025, which was down 297.57% from $23.4 million recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Non-Current Assets peaked at $24.1 million during Q3 2024, and registered a low of $19.2 million during Q1 2021.
  • For the 5-year period, Northwest Biotherapeutics' Non-Current Assets averaged around $22.3 million, with its median value being $22.9 million (2021).
  • In the last 5 years, Northwest Biotherapeutics' Non-Current Assets soared by 24516.59% in 2021 and then plummeted by 1176.52% in 2022.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Non-Current Assets stood at $22.9 million in 2021, then fell by 4.25% to $21.9 million in 2022, then increased by 8.41% to $23.7 million in 2023, then decreased by 4.52% to $22.7 million in 2024, then rose by 3.29% to $23.4 million in 2025.
  • Its last three reported values are $23.4 million in Q3 2025, $23.4 million for Q2 2025, and $22.8 million during Q1 2025.